The incidence of venous thromboembolism in COVID-19 patients was 31.9% and specifically, of DVT, it was 20.2%. Patients with male sex, elevated C-reactive protein, and elevated platelet count at admission were the ones with the highest risk of venous thromboembolism in a COVID-19 context. Mortality in venous thromboembolism in COVID-19 patients increased in the presence of active malignancy, disseminated intravascular coagulation, and increased D-dimer. The gene discussed is CRP; the disease is COVID-19.